Pharma & biotech

ALK and Torii Pharmaceutical strengthen alliance with new allergy tablet vaccine agreement

With Tuesday’s agreement with Japanese Torii Pharmaceutical, ALK now has a third tablet vaccine in the pipeline in the partnership.
From left Peter Halling, CEO of ALK; Goichi Matsuda, Senior Executive Officer of Torii: Atsuyuki Kakee, Head of Innovation at Torii and Søren Niegel, Chief Commercial Officer of ALK. | Photo: Alk / Pr
From left Peter Halling, CEO of ALK; Goichi Matsuda, Senior Executive Officer of Torii: Atsuyuki Kakee, Head of Innovation at Torii and Søren Niegel, Chief Commercial Officer of ALK. | Photo: Alk / Pr
by ALBERT RØNNING-ANDERSSON

Getting pharmaceutical products approved in Japan is a complicated process, and ALK’s long-standing partnership with Torii Pharmaceutical is therefore of great importance to the Danish allergy company, Søren Niegel, Chief Commercial Officer at ALK, tells MedWatch.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
    • Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
    Must contain at least 2 characters
    Must contain at least 2 characters

    Get full access for you and your coworkers

    Start a free company trial today

    Share article

    Related articles

    Sign up for our newsletter

    Stay ahead of development by receiving our newsletter on the latest sector knowledge.

    Newsletter terms

    Front page now

    Further reading

    Jobs